In the present cohort study of ACEI-treated patients with CHF, we examined the prognostic value of two distinct pharmacogenetic scores A and B that have previously been found to influence ACEI efficacy and ACE activity in patients with stable IHD and hypertension, respectively. Here, ACE is linked to hypertensive disorder.